SecBot SecBot
PRESS-RELEASE ·Filed Apr 29, 2026

MESO

Mesoblast Limited
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The EPS miss is overshadowed by strong Ryoncil revenue trajectory, pipeline catalysts (CLBP Phase 3 enrollment complete, adult SR-aGvHD trial starting, DMD IND cleared), and cash conservation. The stock has already repriced higher on prior catalysts, watch for CLBP Phase 3 top-line data readout and adult SR-aGvHD trial enrollment updates as next key events. The CAR-MSC platform acquisition adds optionality in autoimmune indications.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.67
T+0 close · Apr 29, 2026 · via day close
Latest settled
−7.08%
T+60 · $14.56
Vs SPY
−10.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $15.67entry
  2. T+1 · 7mo ago +0.45%α +0.23% · $15.74
  3. T+5 · 6mo ago −5.55%α −7.28% · $14.80
  4. T+20 · 6mo ago −1.72%α −6.95% · $15.40
  5. T+60 · 4mo ago −7.08%α −10.19% · $14.56

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast reported Q3 FY2026 results with Ryoncil net revenue of $30.3M, bringing cumulative launch revenue to ~$100M. EPS of -$0.07 missed consensus of -$0.03, but the company achieved its pivotal Phase 3 trial recruitment target for chronic low back pain and reduced net operating cash spend to $4.1M.

Key Financial Metrics

EPS
−$0.07
est −$0.03 · -133.3%
Revenue
$30.3M
Rating
miss

Key Facts

  • Ryoncil net revenue $30.3M for Q3 FY2026; cumulative launch revenue approaching $100M
  • EPS -$0.07 vs consensus -$0.03 (133% miss)
  • Net operating cash spend reduced to $4.1M from prior levels
  • Cash balance $122M at March 31, 2026
  • Pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain achieved patient recruitment target
  • FDA cleared label extension trial for Ryoncil in adult SR-aGvHD; IND clearance for Duchenne muscular dystrophy registrational trial
  • Acquired exclusive worldwide license to CAR technology platform for precision-enhanced MSC products
  • Inaugural R&D day held April 8 highlighting label expansion and blockbuster opportunities

Financial Impact

Ryoncil revenue run-rate approaching $120M annualized; net cash spend reduced to $4.1M/quarter; $122M cash position provides ~7 years of runway at current burn

revenuecash flowoperating expenses

Risk Factors

  • EPS miss of 133% vs consensus may pressure near-term sentiment
  • Ryoncil revenue growth trajectory depends on continued commercial execution and label expansion approvals
  • CLBP Phase 3 trial success is not guaranteed; failure would remove a major pipeline value driver
  • Dilution risk from potential future capital raises despite current $122M cash position
  • Biotech sector volatility and OTC listing may amplify price swings

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3284394

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026